These results confirm that PKU GOLIKE’s prolonged-release profile provides superior metabolic control during extended fasting periods compared to standard amino acid protein substitutes. The Company ...

BioMarin Pharma has had another setback in its gene therapy development programme, announcing this morning that the FDA has placed a phase 1/2 trial of its candidate for phenylketonuria (PKU ...

Shares in Relief Therapeutics rose after it said a clinical trial of its protein-substitute treatment improved metabolic control. Shares in early trade were up 14% at 4.43 Swiss francs and have more ...

Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.

Considering taking supplements to treat phenylketonuria pku? Below is a list of common natural remedies used to treat or reduce the symptoms of phenylketonuria pku. Follow the links to read common ...

Titled “The Benefits of a Prolonged-Release Protein Substitute with Similarities to Natural Proteins as a Treatment for Phenylketonuria,” the summary was co-authored by PKU specialists with ...

a clinical-stage gene therapy candidate for the treatment of Phenylketonuria (PKU). "We are pleased with the results from our investigator-initiated trial, as they show great promise for NGGT002 ...

Titled "The Benefits of a Prolonged-Release Protein Substitute with Similarities to Natural Proteins as a Treatment for Phenylketonuria," the summary was co-authored by PKU specialists with insights ...